BiomX Inc. financial data

Symbol
PHGE on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
22 Einstein St., Floor 4, Ness Ziona, Israel
Fiscal year end
December 31
Former names
Chardan Healthcare Acquisition Corp. (to 10/23/2019)
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 372 % +56.3%
Return On Equity -88.7 % +63.3%
Return On Assets -28 % +62.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25M shares -54.8%
Common Stock, Shares, Outstanding 18.2M shares +285%
Entity Public Float 21.4M USD +29.4%
Common Stock, Value, Issued 6K USD +100%
Weighted Average Number of Shares Outstanding, Basic 12M shares +134%
Weighted Average Number of Shares Outstanding, Diluted 13.1M shares +156%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.7M USD +47.7%
General and Administrative Expense 11.8M USD +36.1%
Operating Income (Loss) -44.5M USD -75.6%
Nonoperating Income (Expense) 332K USD -13.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.7M USD +32.3%
Income Tax Expense (Benefit) 19K USD -68.9%
Net Income (Loss) Attributable to Parent -17.7M USD +32.3%
Earnings Per Share, Basic 1.47 USD/shares -71.2%
Earnings Per Share, Diluted 3.36 USD/shares -34.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.9M USD +13.1%
Other Assets, Current 2.71M USD +53.1%
Assets, Current 20.5M USD +16.4%
Property, Plant and Equipment, Net 5.05M USD +29.3%
Operating Lease, Right-of-Use Asset 5.46M USD +56.1%
Goodwill 801K USD
Other Assets, Noncurrent 96K USD
Assets 43.2M USD +72.7%
Accounts Payable, Current 1.36M USD -2.58%
Liabilities, Current 8.27M USD -26%
Contract with Customer, Liability, Noncurrent 1.98M USD 0%
Operating Lease, Liability, Noncurrent 8.45M USD +161%
Other Liabilities, Noncurrent 77K USD -50.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -143M USD -22.7%
Retained Earnings (Accumulated Deficit) -181M USD -10.9%
Stockholders' Equity Attributable to Parent 24.1M USD +684%
Liabilities and Equity 43.2M USD +72.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.4M USD -125%
Net Cash Provided by (Used in) Financing Activities 39M USD +3612%
Net Cash Provided by (Used in) Investing Activities 663K USD -66.7%
Common Stock, Shares Authorized 750M shares +525%
Common Stock, Shares, Issued 18.2M shares +285%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.01M USD +88.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18M USD +13.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.42M USD +187%
Deferred Tax Assets, Valuation Allowance 48.8M USD +51.9%
Deferred Tax Assets, Gross 55.6M USD +67.8%
Operating Lease, Liability 9.58M USD +145%
Payments to Acquire Property, Plant, and Equipment 10K USD -50%
Lessee, Operating Lease, Liability, to be Paid 12.5M USD +164%
Property, Plant and Equipment, Gross 10.5M USD +42.8%
Operating Lease, Liability, Current 1.13M USD +69.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.98M USD +188%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.95M USD +184%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.95M USD +246%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.02M USD +193%
Deferred Tax Assets, Operating Loss Carryforwards 42.5M USD +46.2%
Preferred Stock, Shares Issued 148K shares
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.05M USD +634%
Operating Lease, Payments 134K USD
Additional Paid in Capital 186M USD +12.1%
Preferred Stock, Shares Outstanding 148K shares
Share-based Payment Arrangement, Expense 829K USD +325%
Interest Expense 2.69M USD +23.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%